Sept 25 (Reuters) – The US Food and Drug Administration has approved AbbVie’s drug for Parkinson’s disease in adults, the health regulator’s website showed on Friday.
The drug tavapadon, with the brand name Juvmo, comes as a once-a-day pill.
Parkinson’s is a long-term brain condition that gradually damages movement control, often causing tremors, stiffness and balance issues.
AbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
